Zai Lab EPS - Earnings per Share 2016-2022 | ZLAB
Zai Lab eps - earnings per share from 2016 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Zai Lab Annual EPS |
2021 |
$-7.58 |
2020 |
$-3.46 |
2019 |
$-3.03 |
2018 |
$-2.64 |
2017 |
$-2.32 |
2016 |
$-3.97 |
2015 |
$-2.07 |
Zai Lab Quarterly EPS |
2022-03-31 |
$-0.86 |
2021-12-31 |
$-2.17 |
2021-09-30 |
$-1.01 |
2021-06-30 |
$-1.76 |
2021-03-31 |
$-2.64 |
2020-12-31 |
$-0.88 |
2020-09-30 |
$-0.84 |
2020-06-30 |
$0.00 |
2020-03-31 |
$-0.66 |
2019-12-31 |
$0.00 |
2019-09-30 |
$0.00 |
2019-06-30 |
$0.00 |
2018-12-31 |
$0.00 |
2017-12-31 |
$0.00 |
2017-06-30 |
$0.00 |
2016-12-31 |
$0.00 |
2015-12-31 |
$0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$3.497B |
$0.144B |
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
|